Glenmark Pharmaceuticals Inc., Usa (Glenmark) Has Received Final Approval By The United States Food & Drug Administration (Fda) For Its Lacosamide Tablets Usp, 50 Mg, 100 Mg, 150 Mg And 200 Mg, The Generic Version Of Vimpat Tablets, 50 Mg, 100 Mg, 150 Mg And 200 Mg Of Ucb, Inc. The Company Plans To Launch The Product Immediately.Commenting On The Development, Robert Crockart, Chief Commercial Officer, Glenmark Pharmaceuticals Ltd, Said,
